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Abstract
Background: A study was conducted to evaluate and compare the effectiveness of two different oral flea and tick
products to control flea infestations, reduce pruritus and minimize dermatologic lesions over a 12 week period on
naturally infested dogs in west central FL USA.
Methods: Thirty-four dogs with natural flea infestations living in 17 homes were treated once with a fluralaner
chew on study day 0. Another 27 dogs living in 17 different homes were treated orally with an afoxolaner
chewable on day 0, once between days 28–30 and once again between days 54–60. All products were
administered according to label directions by study investigators. Flea populations on pets were assessed using
visual area counts and premise flea infestations were assessed using intermittent-light flea traps on days 0, 7, 14, 21,
and once between days 28–30, 40–45, 54–60 and 82–86. Dermatologic assessments were conducted on day 0 and
once monthly. Pruritus assessments were conducted by owners throughout the study. No concurrent treatments
for existing skin disease (antibiotics, anti-inflammatories, anti-fungals) were allowed.
Results: Following the first administration of fluralaner or afoxolaner, flea populations on pets were reduced by 99.
0 % and 99.3 %, respectively within 7 days. Flea populations on the fluralaner treated dogs were 0 (100 % efficacy)
on days 54–60 and 82–86 after the administration of a single dose on day 0. Administration of 3 monthly doses of
afoxolaner reduced flea populations by 100 % on days 82–86. Flea numbers in indoor-premises were markedly
reduced in both treatment groups by days 82–86, with 100 % and 98.9 % reductions in flea trap counts in the
fluralaner and afoxolaner treatment groups, respectively. Marked improvement was observed in FAD lesion scoring,
Atopic Dermatitis lesions scoring (CADESI-4) and pruritus scores with both formulations.
Conclusions: In a clinical field investigation conducted during the summer of 2015 in subtropical Florida, a single
administration of an oral fluralaner chew completely eliminated dog and premises flea infestations and markedly reduced
dermatology lesions and pruritus. Three monthly doses of the afoxolaner chewable also eliminated flea infestations in
dogs, markedly reduced premises’ flea populations and similarly improved dermatology lesions and pruritus.
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Background
Fleas are an extremely important blood sucking parasite
that infest dogs and cats worldwide. Flea infestations are
medically and economically important because fleas are
not just irritating to dogs and cats, they can produce
anemia, allergic dermatitis, carry several bacterial patho-
gens, and serve as the intermediate host for cestode and
filarid parasites [1].
A number of field studies conducted in Australia,
Europe and the United States have documented that a
variety of modern topical and oral flea products can
effectively eliminate flea infestations [2–14]. Compounds
such as afoxolaner, dinotefuran-pyriproxyfen, fipronil (±,
(s)-methoprene) imidacloprid, indoxacarb, fluralaner,
lufenuron (+pyrethrin spray or + nitenpyram tablets),
selamectin, and spinosad have been found in these vari-
ous studies to be effective in reducing or eliminating flea
infestations on naturally infested dogs and cats without
the need for premises treatments [2–14].
Fluralaner and afoxolaner are recently introduced oral
flea and tick adulticides in the isoxazoline class of drugs.
Both drugs work as GABA-Chloride antagonists causing
over excitation of the insect and arachnid nervous
system and rapid ectoparasite death [15, 16]. Both mole-
cules have demonstrated rapid and persistent efficacy
against fleas and multiple species of ticks [17, 18].
Following the administration of a fluralaner chew,
efficacy has been maintained against fleas in both field
and laboratory studies for 12 weeks [14, 19, 20]. A single
dose of a fluralaner chew has been shown to start work-
ing within 2 h of administration, eliminating 88 % of an
existing flea population on dogs within 4 h [19]. In a
separate study fluralaner killed newly acquired female
fleas rapidly enough that no eggs were laid after repeated
infestations for 120 days [21]. In multicentric field stud-
ies evaluating dogs not managed with associated medica-
tions, fluralaner’s rapid and pronounced efficacy against
fleas improved clinical signs associated with Flea Allergy
Dermatitis (FAD) by 80–96 % [14] and 85.7 % [20]. In
those studies, the veterinarian’s experience was used to
determine if the signs were consistent with FAD.
Recently, two more controlled studies using fluralaner
were performed showing 98.8 % and 100 % resolution of
FAD signs within 12 weeks, respectively in 20 dogs diag-
nosed with FAD [22, 23]. In one study clinical signs of
FAD were based upon clinical examination, and a posi-
tive response on serologic and intradermal evaluations
of flea allergen [23]. The other study was an open pre-
treatment versus post-treatment assessment, where
clinical signs of FAD were clinically evaluated by a veter-
inary dermatologist [22].
Afoxolaner has an onset of activity of 4 h against fleas
[24] and has been shown to reduce flea egg production by
greater than 99 % for one month [25]. A laboratory study
comparing one dose of fluralaner and 3 doses of afoxola-
ner administered 28 days apart showed a statistically
significant difference in flea adulticide efficacy between
products at 6 and 12 h post-infestation time points on
days 70 and 84. Throughout the 84 day study there was
no statistically significant difference in flea reductions
between products when assessed at 24 h after each weekly
infestation with efficacies of 99.6 % and 100 % respectively
on day 84 [26]. The flea reduction efficacy of afoxolaner
administered monthly to client owned dogs in Tampa, FL
was 100 % within 6 weeks [11].
The objective of this study was to evaluate and compare
the efficacy of fluralaner and afoxolaner oral treatments
against fleas on naturally infested dogs in subtropical
Florida using both premises and on-animal flea population
estimating techniques. Additionally, this study was
designed to determine the effect of these treatments on
reducing flea associated dermatitis and pruritus. The
methodology used in this investigation eliminated client
compliance and adherence problems because investigators
administered products to all animals.
Methods
Home and pet study inclusion criteria
Through referrals from Sunshine Animal Hospital, Tampa,
FL, Animal Dermatology South, New Port Richey, FL, and
advertisements on CRAIGSLIST®, 36 private residences
were selected for inclusion in the study from May 19 - June
08, 2015.
Homes were selected based on the following criteria:
1) a minimum of five fleas observed in area flea counts
on at least one dog at the residence; 2) a minimum of
five fleas collected in a 16–24 h period in two intermit-
tent light flea traps; 3) one to five healthy, non-fractious
dogs at the residence (no cats); 4) qualifying dogs must
spend > 50 % of their time in the indoor premises; 5)
homeowner’s willingness to participate in the 3 month
study; 6) owners agreeing not to use any other topical or
premise flea control products during the study and no
history of residual topical or oral flea products used in
the previous 30 days; 7) owners agreeing not to bring
any other mammalian pets into the household for the
duration of the study; 8) no pregnant or nursing dogs in
the household; 9) dogs qualifying for the study must be >
6 months of age and > 4.4 lb; 10) completion of a ques-
tionnaire concerning pet habits, visiting pets, previous
flea treatments and personal observations around their
residence concerning wildlife and feral cats and 11)
owners willingness to sign an informed consent form.
Treatment groups
Homes and dogs meeting these criteria were placed into
1 of 2 treatment groups. Home entry numbers (1–36)
were each assigned a random number by Excel (Excel
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2013) and blocked into groups of 2. The highest random
number within each block was assigned to group 1 and
lowest to group 2.
Dogs in treatment group 1 were administered an oral
fluralaner chew (Bravecto®, Merck Animal Health) once
on day 0 according to label dosing recommendations.
Dogs in group 2 were administered an oral afoxolaner
chewable (NexGard® Chewables, Merial) according to
the label dosing recommendations 3 times during the
82–86 day study: once on day 0, once between days 28–
30 and once again between days 54–60.
All dogs were weighed prior to each treatment and
products were administered by members of the Kansas
State University (K-State) Flea Team who were not blinded
to treatment groups. While only dogs meeting the inclu-
sion criteria were included in the study for data collection,
all dogs living at a residence were administered group
appropriate treatment. No other on-animal or oral flea
product or premises flea treatments were used during the
12 week study. There were no restrictions on the animals
regarding exposure to rain, swimming, bathing, or move-
ment outdoors.
This study was conducted without a placebo control
group. While the use of a non-treated group might have
provided a better evaluation of the performance of the
two treatment regimens, it is the opinion of these authors
that the large flea infestations commonly encountered in
the Tampa, FL area preclude the use of a non-treated
group. Withholding treatment would be detrimental to
the health and welfare of both the dogs, and potentially
even the humans in a household.
Flea population assessment
The numbers of adult fleas present in the indoor prem-
ises were assessed using intermittent light traps [3–8, 10,
11, 27, 28]. One trap was placed in each of two rooms
for 16 to 24-h. Rooms were selected based on where the
dog(s) spent most of the time or where owners had
observed fleas. Once rooms were selected, the traps were
returned to the same rooms in the same location at
every counting period. Fleas collected on the adhesive
pads of the traps were enumerated and identified by
microscopic observation as to determine species.
The flea population on each pet was assessed using a
visual area count methodology [3–8, 10, 11, 29]. Area
counts were performed at five locations on each animal;
dorsal midline, tail head, left lateral, right lateral, and in-
guinal region. Area counts were limited to one minute
per location and conducted by parting the hair against
the lay using both hands until the area was covered.
Maximum number of fleas per zone was capped at 50;
therefore, the maximum total area flea counts for a dog
was 250. Area (on-animal) and environment flea counts
were conducted ± 1 day on days 0, 7, 14, 21, then once
between days 28–30, 40–45, 54–60 and 82–86.
Personnel conducting pet and premises flea counts were
not blinded to treatment groups.
Evaluation of skin disease and pruritus
At visits occurring on days 0, 14, 28–30, 40–45, 54–60,
and 82–86, the owner was asked to rate the pruritus
level of the qualifying dog(s) in the home on a non-
numeric scale using a data capture form. This form pro-
vides 6 written descriptions of increasing pruritus sever-
ity, from “Normal dog—I do not think itching is a
problem” through “Extremely severe itching…” (Fig. 1)
[30, 31]. Following the rating of pruritus by the owner, a
numeric scale of 0–10 was placed on the form and a
numeric assessment of the pruritus level was recorded.
Owners did not see and were not informed of the
numerical scale or their dog(s) score during the study. In
a household with more than one owner, only one owner
was allowed to assess the pruritus level of the dog(s)
throughout the study.
Masked as to treatment groups, clinical dermatologic
observations were made on days 0, 30, 60, and 84 of the
study (±3 days) of all qualifying dogs in the homes. To
ensure repeatability of results, a single Board-certified
veterinary dermatologist (MC) made all of the observa-
tions. To assess skin lesions two different systems were
used. Dermatologic signs potentially associated with Flea
Allergy Dermatitis were assessed using a flea bite hyper-
sensitivity severity scale that evaluated erythema,
papules, crusts, scale, alopecia, and excoriation [32].
Each of these categories was graded by the board-
certified veterinary dermatologist using a scale from 0 to
3, 0 = no signs, 1 =mild, 2 =moderate, 3 = severe. Three
body sites were assessed, (1) dorsum, from the withers
to the base of the tail, (2) left and right lateral thorax,
just caudal to the elbow and extending to the last rib, (3)
“flea triangle”, including the dorsal lumbosacral region,
caudomedial thighs, and ventral abdomen (Table 1) [32].
Scores for each of the six dermatology categories, for
each body site, and the total sum of all of these sites and
conditions were calculated for each dog at each observa-
tion. Additionally, dogs were also assessed by the derma-
tologist using the canine atopic dermatitis (CAD) extent
and severity index scoring system (CADESI-4) (Table 2)
[33], as a means to assess the skin in regions more
commonly thought to be abnormal in atopic dermatitis
patients. There is, however, overlap in the two scoring
systems.
Data analysis
The dog and trap counts were analyzed separately at
each time point, using the two-sample t test to test for
differences in the two groups. Statistical analysis was
performed using SAS version 9.1 or higher. The animal
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and trap flea count data were transformed prior to
analysis using the Y = log (x + 1) transformation.
The log transformed flea counts on dogs were analyzed
by a mixed linear model with repeated measure including
treatment, day, treatment by day as the fixed effects; and
household, and animal as random effects. The log trans-
formed flea counts in traps were analyzed by a mixed
linear model with repeated measure including treatment,
day, and treatment by day as the fixed effects and house-
hold as random effect.
A Kenward-Rogers adjustment was used to deter-
mine the denominator degree of freedom for hypoth-
esis. Akaike’s Information Criterion (AIC) was used
as the criterion to select the covariance structure for
repeated measures.
The dermatology, pruritus and CADESI scores were
analyzed by the same mixed linear model with repeated
measure as that for the flea counts on dogs.
Percentages of animals without fleas and the percent-
ages of homes without fleas (defined as homes where no
fleas were recovered on either traps or dogs), were ana-
lyzed and compared.
All comparisons were made between treatment groups
on each data collection day and also between each
collection day and the baseline (Day 0) values within
each treatment group.
A two-tailed significance test was used for the com-
parison and significance was declared when P < 0.05 and
90 % confidence intervals were constructed for the dif-
ferences between treatment groups for the equivalence
declaration.
The primary software was SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA).
Table 1 Flea bite hypersensitivity severity scoring form
Site 1
(Dorsum)
Site 2
(Lateral Thorax)
Site 3
(Flea Triangle)
Sum of all sites
and categories
Erythema
Papules
Crusts
Scale
Alopecia
Excoriation
Total scores
Scale:
0 – no signs
1 – mild
2 – moderate
3 – severe
Fig. 1 Pruritus Visual Analogue Scale
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Percent control of fleas counts were calculated using
geometric means with Abbott’s formula:
Efficacy %ð Þ ¼ 100 x MB –MCð Þ=MB
Where:
– MC is the geometric mean number of fleas on flea
count day
– MB is the geometric mean number of live fleas
count on baseline.
Note: Efficacy was calculated using both geometric
and arithmetic means; however, geometric means were
considered as the primary approach for effectiveness
evaluation.
Results
Thirty-six homes were originally enrolled in the study.
However, two households (one in the fluralaner group
and one in the afoxolaner group) did not remain in the
study for at least 30 days; data from those households
were not included. In the fluralaner group, the owner
was not reliable in scheduling rechecks following initial
treatment. The owner of the afoxolaner household
brought puppies under 6 months of age into the home
within three weeks of treatment. Several other homes
and/or dogs did not complete the entire 12-week study
but remained up to days 40–45. Data from those homes
and dogs were included in data analysis up to the point
that follow up was no longer possible. In the fluralaner
group, one home (1 dog) was lost after the day 40–45
recheck because the owner was unreachable by phone
and was not found at the residence. In the afoxolaner
group one dog was lost prior to the day 54–60 after
succumbing to apparent “heat stroke”. The other on
study dog in the home completed the study. A home
with two dogs treated with afoxolaner was lost on the
last day of the study because the owner failed to appear
for the appointment. A fourth afoxolaner dog was lost
just prior to the last recheck when the owner moved out
of the range of the study.
In the 17 homes in the fluralaner group that remained
in the study beyond days 40–45 there were 34 dogs (avg.
15.1 kg; range 2.0–36.0 kg) enrolled. On day 0 dogs were
treated in accordance with label direction and received a
mean oral dose of 38.9 mg/kg (range 27.2–56.3 mg/kg)
fluralaner. There were an additional 9 dogs in these homes
Table 2 Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4) scoring form
Erythema Lichenification Excoriations and/or Alopecia Total
Perilabial Area (left and right combined) 1
Medial Pinnae
(concave pinnae)
Left 2
Right 3
Axillae Left 4
Right 5
Front Paws
(dorsal and palmar sides combined)
Left 6
Right 7
Hind Paws
(dorsal and palmar sides combined)
Left 8
Right 9
Cubital Flexor
(elbow folds)
Left 10
Right 11
Palmar Metacarpal
(from carpal to metacarpal pads)
Left 12
Right 13
Flanks Left 14
Right 15
Inguinal Areas
(groin)
Left 16
Right 17
Abdomen 18
Perineum
(from vulva/scrotum to anus)
19
Ventral Tail
(proximal)
20
Grade each site and each lesion type:
None: 0; mild: 1; moderate: 2; severe: 3;
Total score (20x3x3=180)
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that did not qualify for the study because they had an
insufficient numbers of fleas (< 5) on day 0, resided per-
manently outdoors, were brought into the home after the
enrollment date, or could not be safely handled by flea
team members during flea counts. Therefore, there were a
total of 43 dogs resident in the 17 homes that were treated
with fluralaner on day 0.
In the 17 homes in the afoxolaner group that remained
in the study beyond days 40–45, there were 27 dogs
(avg. 16.7 kg; range 3.6–36.8 kg) enrolled in the study.
On day 0 the dogs were treated in accordance with label
direction and received a mean dose of 3.6 mg/kg (range
2.7–5.4 mg/kg) afoxolaner. Dogs in the afoxolaner group
were similarly treated by study personnel two additional
times; on day 28–30 and day 54–60. There were an
additional 9 dogs in these homes that did not qualify for
the study because of the same factors listed previously.
Therefore, there were a total of 36 dogs resident in the
17 homes that were treated with afoxolaner on day 0.
On day 0, pets in the fluralaner treatment group had a
geometric mean of 28.3 (range 5–155) fleas observed in
area counts (Table 3). Pets in the afoxolaner treatment
group had a geometric mean of 20.4 (range 5–178) fleas
observed in area counts on day 0. The geometric mean flea
count of fluralaner treated dogs was significantly higher on
Day 0 than that of afoxolaner treated dogs (P = 0.004)
Within 7 days of administration of fluralaner or afoxolaner
the flea counts were reduced by 99.00 % and 99.3 %,
respectively (Table 3). By days 28–30 the flea counts in the
fluralaner treatment group were reduced by 100.0 % and
reductions remained at 99.9 % to 100 % for the remainder
of the 12-week study following a single oral dose on day 0
(Table 3). Afoxolaner also markedly reduced flea popula-
tions, with 99.9 % control on day 28–30 and 99.9 %–100 %
control out to days 82–86 after 3 monthly doses. (Table 3).
Both products significantly reduced flea counts on dogs at
each time point (P <0.001). The flea counts of the two
treatment groups were not significantly different on any of
the post-treatment count days (P ≥ 0.327).
The number of flea free dogs in both groups following
treatment were similar (Table 3). Following a single oral dose
of fluralaner 88.2 % (30/34) of dogs were completely flea free
by day 14 and only a single flea was found on one dog be-
tween days 28–30 and days 82–86, with all dogs flea free at
the end of the study. Similarly 81.5 % (22/27) of the dogs in
the afoxolaner treatment group were flea free by day 14 and
only a single flea was found at two time points between days
28–30 and 82–86 following three monthly doses. All dogs
were flea free by the end of the study (Table 3). Again, both
products produced statistically significant more flea free dogs
at each time point relative to study onset, (P<0.001) but
there was no statistically significant difference in the number
of flea free dogs between treatment groups (P ≥ 0.4407).
During the entire 12-week study, 1,267 fleas were trapped
in the 34 residences using intermittent light traps and all
were identified as Ctenocephalides felis felis, the cat flea. On
day 0, the traps collected a geometric mean of 19.2 (range
6–122) and 14.0 (range 6–167) fleas in homes in the flurala-
ner and afoxolaner treatment groups, respectively (Table 4).
Reductions in premises flea trap counts were 99.6 % and
100.0 % by days 28–30 and 82–86, respectively in the homes
where pets were treated with fluralaner (Table 4). Reduc-
tions in premises flea trap counts were similar in homes
where pets were treated with afoxolaner, with 96.7 % and
98.9 % by days 28–30 and 82–86, respectively (Table 4).
Households without fleas on pets or in traps were
considered flea free. Treatment with one dose of flurala-
ner resulted in 88.2 % (15/17) flea free households
Table 3 On-animal flea counts in naturally infested homes when dogs were administered either fluralaner or afoxolaner oral treatments
Treatment
group
# dogs at
day 0
Days post-Treatmenta
Day 0 Day 7 Day 14 Day 21 Day 28–30 Day 40–45 Day 54–60 Day 82–86
Fluralanerb 34 Geomeand 28.3 0.3 0.1 0.1 0.0 0.0 0.0 0.0
range (5–155) (0–6) (0–3) (0–2) (0–0) (0–1) (0–0) (0–0)
% controle 99.0 99.6 99.8 100.0 99.9 100.0 100.0
% (#) dogs with
no fleas
0.0
(0/34)
76.5
(26/34)
88.2
(30/34)
94.1
(32/34)
100.0
(34/34)
97.1
(33/34)
100.0
(33/33)
100.0
(33/33)
Afoxolanerc 27 Geomean 20.4 0.1 0.2 0.1 0.0 0.0 0.0 0.0
range (5–178) (0–4) (0–2) (0–3) (0–1) (0–0) (0–1) (0–0)
% control 99.3 99.2 99.6 99.9 100.0 99.9 100.0
% (#) dogs with
no fleas
0.0
(0/27)
85.2
(23/27)
81.5
(22/27)
92.6
(25/27)
96.3
(26/27)
100.0
(27/27)
96.2
(25/26)
100.0
(23/23)
aIn both groups, dogs were treated on day 0. In the afoxolaner group, dogs were also treated once between days 28–30 and once between days 54–60
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
dGeometric mean numbers of fleas in visual area counts on pets
e{(Day 0 geometric mean animal area flea counts—day x geometric mean animal area flea counts)/day 0 geometric mean animal area flea counts)} x 100
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within 28–30 days of treatment and 100 % of households
(16/16) free of fleas at week 12. Treatment with three
monthly doses of afoxolaner resulted in 70.6 % (12/17)
flea free households by day 28–30 and 80 % (12/15) of
households free of fleas at week 12. There was no statis-
tically significant difference in the number of flea free
households between treatment groups (P ≥ 0.1012).
Dogs in the fluralaner and afoxolaner treatment
groups had mean total flea bite hypersensitivity severity
lesion scores of 12.8 (range 0–31) and 10.7 (range 1–30),
respectively (Table 5) on day 0. By the end of the three-
month study flea bite hypersensitivity severity lesion
scores in the dogs were reduced to 1.8 (85.5 % improve-
ment) and 2.0 (81.3 % improvement), in the fluralaner
and afoxolaner treatment groups respectively (Table 5).
Both products produced statistically significant reduc-
tions in signs of flea bite hypersensitivity relative to
study onset, (P <0.001), but there was no statistically sig-
nificant difference between treatment groups (P ≥ 0.087).
Interestingly, CADESI-4 lesion scores were also similarly
reduced. On day 0, dogs in the fluralaner and afoxolaner
treatment groups had mean total CADESI-4 lesion scores
of 51.5 (range 9–80) and 51.7 (range 3–91), respectively
(Table 6). By the end of the three-month study CADESI-4
lesion scores in the dogs were reduced to 9.1 (82.3 %
improvement) in the fluralaner treatment group and 8.7
(83.2 % improvement), in the afoxolaner treatment group
(Table 6). Both products produced statistically significant
reductions in CADESI-4 lesion scores relative to study
onset, (P <0.001), but there was no statistically significant
difference between treatment groups (P≥ 0.493).
Owner assessed pruritus scores showed rapid and
marked improvement in both treatment groups. On day 0,
dogs in the fluralaner and afoxolaner treatment groups
had mean pruritus visual analogue scale (PVAS) scores of
7.3 (range 2.2–10) and 7.1 (range 2.7–10), respectively
(Table 6). Within 2 weeks post-treatment, mean pruritus
scores had dropped by 71.0 % (2.1) and 73.8 % (1.9) in the
fluralaner and afoxolaner treatment groups, respectively
(Table 7). By the end of the study the mean pruritus scores
in both groups had fallen to 0.9 and 0.7, in the fluralaner
and afoxolaner treatment groups, respectively (Table 7).
Both products produced statistically significant reductions
in PVAS scores relative to study onset, (P <0.001), but
there was no statistically significant difference between
treatment groups (P ≥ 0.695).
Nine adverse events were reported in treated dogs
in both groups during the course of the trial. In the
Table 4 Fleas recovered in premises flea traps in naturally infested homes when dogs were administered either fluralaner or
afoxolaner chews
Treatment group # homes Days post-Treatmenta
Day 0 Day 7 Day 14 Day 21 Day 28–30 Day 40–45 Day 54–60 Day 82–86
Fluralanerb 17 Geomeand 19.2 1.5 0.5 1.2 0.1 0.1 0.0 0.0
% controle 92.4 97.3 93.9 99.6 99.7 99.8 100.0
range (6–122) (0–8) (0–5) (0–4) (0–1) (0–2) (0–1) (0–0)
Afoxolanerc 17 Geomean 14.0 1.9 1.7 1.4 0.5 0.3 0.3 0.1
% control 86.5 88.0 90.2 96.7 98.2 97.8 98.9
range (6–167) (0–10) (0–12) (0–23) (0–26) (0–11) (0–8) (0–1)
a In both groups, dogs were treated on day 0. In the afoxolaner group dogs were also treated once between days 28–30 and once between days 54–60
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
dGeometric mean numbers of fleas recovered in two intermittent light flea traps averaged within households
e{(Day 0 geometric mean trap flea counts—day x geometric mean trap flea counts)/day 0 geometric mean trap flea counts)} x 100
Table 5 Assessment of skin lesions using a flea bite
hypersensitivity severity scale for dogs naturally infested with fleas
and administered either fluralaner or afoxolaner oral treatments
Treatment
group
Days post-treatmenta
Day 0 Day 28–30 Day 54–60 Day 82–86
Fluralanerb # Dogs 34 34 33 33
Mean Scored 12.8 5.4 3.7 1.8
STDEV 8.22 4.13 3.80 1.64
Range (0–31) (0–21) (0–21) (0–7)
Reductione 58.1 % 71.0 % 85.5 %
Afoxolanerc # Dogs 27 27 26 23
Mean Scored 10.7 4.9 2.7 2.0
STDEV 7.15 3.35 2.76 2.30
Range (1–30) (0–12) (0–13) (0–8)
Reduction 54.0 % 74.5 % 81.3 %
aIn both groups dogs were treated on day 0. In the afoxolaner group dogs
were also treated once between days 28–30 and once between days 54–60
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal
Health) according to label directions
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.)
according to label directions
dArithmetic mean Flea Allergy Dermatitis lesion score (Wilkerson et al. Vet
Immunol Immunopathol 99(3–4):179–192, 2004)
e{(Day 0 arithmetic mean score—day x arithmetic mean score)/day 0
arithmetic mean score)} x 100
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fluralaner treatment group, one owner reported that a dog
was lethargic for 1 to 2 days following fluralaner adminis-
tration, and was acting normally on the 3rd day. Another
owner reported that a fluralaner treated dog was lethargic
and had increased pruritus for a few days during the week
following treatment, and was acting normally before the
7 day recheck. Another owner reported that 27 days after
fluralaner treatment, his 2 dogs ate grass and vomited.
Another owner reported that 2 of the 5 fluralaner treated
dogs in the home had periodic episodes of coughing dur-
ing the study. This owner declined offer of diagnostic
evaluation of the two dogs.
In the afoxolaner treatment group an owner reported
that their dog vomited 27 days after treatment, and ap-
peared normal and healthy at retreatment on day 29.
Another owner reported loose stools in an afoxolaner
treated dog from day 9 through day 13. One owner re-
ported that one of five afoxolaner treated dogs in the
household died prior to the day 54–60 evaluation. The
owner assessed the cause as “heat stroke” when the air-
conditioner broke during the day while the owner was
absent. The owner disposed of the dog’s body prior to
informing the study investigators, and it was not possible
to conduct a necropsy.
Table 6 Assessment of skin lesions using the Canine Atopic Dermatitis Extent and Severity Index-4 (CADESI-4) scale for dogs natur-
ally infested with fleas and administered either fluralaner or afoxolaner oral treatments
Treatment group Days post-Treatmenta
Day 0 Day 28–30 Day 54–60 Day 82–86
Fluralanerb # Dogs 34 34 33 33
Mean CADESI - 4 Scored 51.5 20.4 15.2 9.1
STDEV 17.53 8.99 9.95 5.29
Range (9–80) (0–39) (0–40) (0–20)
Reductione 60.4 % 70.5 % 82.3 %
Afoxolanerc # Dogs 27 27 26 23
Mean CADESI - 4 Scored 51.7 18.8 12.7 8.7
STDEV 22.28 14.80 12.51 7.70
Range (3–91) (3–51) (0–48) (0–26)
Reductione 63.6 % 75.4 % 83.2 %
aIn both groups dogs were treated on day 0. In the afoxolaner group, dogs were also treated once between days 28–30 and once between days 54–60
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
dArithmetic mean Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 scores (Olivry et al. Vet Dermatol 25(2):77–85, 2014)
e{(Day 0 arithmetic mean CADESI-4 score – day x arithmetic mean CADESI-4 score)/day 0 arithmetic mean CADESI-4 score)} x 100
Table 7 Owner assessment of pruritus using a visual analogue scale (PVAS) for dogs naturally infested with fleas and administered
either fluralaner or afoxolaner treatments
Treatment
group
Days post-Treatmenta
Day 0 Day 28–30 Day 54–60 Day 82–86
Fluralaner b # Dogs 34 34 33 33
Mean PVAS Scored 7.3 1.7 0.9 0.9
STDEV 2.40 1.8 1.2 1.3
Range (2.2–10) (0-6) (0-4.2) (0-4.2)
Reductione 77.0 % 87.5 % 88.0 %
Afoxolaner c # Dogs 27 27 26 23
Mean PVAS Scored 7.1 1.5 0.7 0.7
STDEV 2.2 1.8 0.9 1.4
Range (2.7–10) (0-6.5) (0-3.6) (0-6.7)
Reduction 79.2 % 89.6 % 89.7 %
aIn both groups dogs were treated on day 0. In the afoxolaner group dogs were also treated once between days 28–30 and once between days 54–60
bDogs were orally administered fluralaner chews (Bravecto® Merck Animal Health) according to label directions
cDogs were orally administered afoxolaner chewables (NexGard® Merial, Inc.) according to label directions
dArithmetic mean pruritus score as assessed by dog owners using the PVAS (Hill et al. Vet Dermatol 18(5):301–308, 2004)
e{(Day 0 arithmetic mean FAD score—day x arithmetic mean FAD score)/day 0 arithmetic mean FAD score)} x 100
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Discussion
Fluralaner chews provided excellent flea control achiev-
ing 99.0 % reduction in geometric mean area flea counts
on dogs within one week and complete elimination of
on-animal flea burdens within 2 months after a single
dosage. There were still no fleas on any dog and none in
any home at the end of the 12-week study. The residual
activity of this formulation was remarkable given the po-
tential for continual flea infestation pressure from
infested indoor and outdoor premises. The afoxolaner
chewables administered monthly also provided good flea
control. Following three monthly oral doses of afoxola-
ner the geometric mean area flea counts on dogs was
also reduced by 100 % by the end of the 12 week study
and > 80 % of homes were flea free. The level of efficacy
observed in this study for the afoxolaner chewable was
very similar to that observed in a previous field study
conducted in west central Florida (Tampa Bay) [11].
The area count technique used in this and previous
in-home investigations in west central Florida has been
shown to detect an average of 23.5 % of the total pet flea
burden [29]. Therefore, average pretreatment total body
flea burdens of dogs in the fluralaner and afoxolaner
treatment groups based on geometric means area counts
of 28.3 and 20.4 can be estimated to be approximately
120 and 86.8 for dogs in this study, respectively.
It is important to note that in previous in-home stud-
ies conducted in west central Florida the percent re-
ductions in on-animal flea counts were often less than
100 % even through 90 days of treatment [3–8, 10]. In
a 2010 study where dogs were treated with either a
dinotefuran-pyriproxyfen or fipronil (s)-methoprene
topical spot-on formulation, only 60.0 % and 55.6 % of
dogs were completely flea free by days 54–60 [8]. In
2013 even though the efficacy against on-animal flea
burdens of monthly topical indoxacarb was 99.1 %, the
number of completely flea free dogs was only 77.1 %,
by the end of the two month study [10]. In that 2013
study, the monthly application of fipronil (s)-metho-
prene topical spot-on only achieved 15.6 % flea free
status by 2 months.
In contrast to these previous studies, when dogs were
administered either fluralaner or afoxolaner oral treat-
ments, 88.2 % and 81.5 % were flea free within 2 weeks
and 100 % and 96.3 % were flea free within 4 weeks, re-
spectively. These data combined with the on-animal flea
count efficacy data are indicating that these isoxazolines
have a very rapid residual speed of kill under natural flea
exposure conditions. Previous reports from a laboratory
study suggest minor differences in the speed of kill may
have clinical consequences [26]. However, this real world
field study demonstrated no statistically significant dif-
ferences between one dose of fluralaner and three doses
of afoxolaner in any of the flea infestation or clinical
parameters assessed. In addition, the continued residual
efficacy of a single oral dose of fluralaner was evidenced
by the fact that from evaluations conducted between
days 28–30 post-treatment up to and including evalua-
tions on week 12, only a single flea was ever found on a
single dog. Furthermore, one administration of fluralaner
per dog cleared all households completely of fleas in the
12 weeks of this study.
In this current study one of the objectives was to assess
the effect of these treatments on reducing dermatitis and
pruritus in treated dogs. Flea allergy dermatitis and atopic
dermatitis are the most common allergic skin diseases in
dogs and cats [34]. To evaluate flea allergy dermatitis we
chose a flea bite hypersensitivity lesional scoring system
that was previously published from a laboratory controlled
FAD induction study [32]. Although multiple validated
scoring systems for canine atopic dermatitis exist, cur-
rently, the International Committee on Allergic Diseases
of Animals (ICADA) recommends CADESI-4, or, canine
atopic dermatitis lesion index (CADLI) as the only two
validated severity scales to score skin lesions of canine
atopic dermatitis patients [33]. CADESI-4 was utilized in
this study for a more thorough dermatologic lesion assess-
ment. It is important to note that a definitive diagnosis of
FAD or CAD was not attained for the patients enrolled in
the study. The intent was to have a single investigator
clinically evaluate each of the study participants utilizing
the aforementioned scoring systems to determine the
clinical relevance of flea control measures when additional
treatments were not provided.
The owner reported pruritus assessment tool (PVAS)
we used was previously validated and used in field trials
[9, 30, 31]. Pruritus is a subjective parameter and is im-
portant in evaluating response to therapy in a patient with
pruritic dermatitis [30, 31]. There was rapid statistically
significant improvement in PVAS scores for patients
receiving fluralaner or afoxolaner despite no concurrent
therapies.
The diagnosis of flea allergy dermatitis is made based on
history, clinical signs, and response to anti-flea therapy [35].
Intradermal allergy testing and serological testing can have
variable results and are not recommended for diagnosis of
flea allergy on their own. Specificity, sensitivity, and accur-
acy of intradermal testing with whole-body flea extracts can
vary, especially if performed in a flea endemic region [35].
Definitive diagnosis of flea allergy dermatitis must be made
by the resolution of clinical signs in response to flea control
and the recurrence of those signs upon re-exposure to fleas.
In this current study there was statistically significant
improvement in the flea bite hypersensitivity severity scores
in both treatment groups. By days 54–60, there was 85.5 %
and 81.3 % improvement with fluralaner and afoxolaner,
respectively. The marked improvement in PVAS as well as
the FAD scores upon treatments with fluralaner and
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afoxolaner supports that most of the participants had
clinical signs attributable to flea exposure.
Diagnosis of canine atopic dermatitis is mainly a diag-
nosis of exclusion that requires a systematic approach
[36, 37]. Diagnosis is based on history, clinical signs, and
ruling out other pruritic diseases that share similar char-
acteristics [36, 37]. Many of the study participants had
lesions consistent with those that can be seen in atopic
dermatitis, however further evaluation would be neces-
sary for this diagnosis to be made. Dogs exhibited clin-
ical signs consistent with atopic dermatitis, though it
was beyond this study to pursue a more definitive diagno-
sis. The improvement of CADESI-4 scores, could support
the concept that there is a threshold for the development
of atopic dermatitis. The concept of threshold for the de-
velopment of atopic dermatitis relates to the allergen load.
When the allergen load is low, no symptoms may be ob-
served, however when a heavy allergen burden exists, clin-
ical disease results [34]. In our study, the elimination of
fleas without the benefit of additional treatments caused
statistically significant improvement in PVAS, CADESI-4,
and FAD scores. Therefore, it is possible that the elimin-
ation of fleas resulted in a reduction of stimuli below the
pruritic threshold, and/or, that the allergen burden was re-
duced such that if participants were atopic dogs, they were
able to experience significant improvement [34].
An adverse event is any clinical sign reported following
treatment administration regardless of causality. Adverse
events were reported following administration of both
fluralaner and afoxolaner in the course of this study. The
reported events in this study may have been treatment as-
sociated or may have been independent of treatment ad-
ministration. All but one of the reports were considered
to be not serious and all of these resolved without treat-
ment, with none of the affected dogs withdrawn from the
study. The afoxolaner treated dog that died was unfortu-
nately not available for necropsy examination.
Despite study protocol requirements that dogs not be
pregnant, breeding or lactating during the 84-day study,
one dog in the fluralaner treated group did become preg-
nant and delivered puppies on study day 49. As fluralaner
is approved for pregnant and lactating dogs, this dog con-
tinued in the study and birthed a healthy litter of puppies.
Conclusions
This clinical field investigation conducted during the sum-
mer of 2015 in subtropical west central Florida clearly dem-
onstrated that these oral isoxazoline formulations rapidly
and effectively controlled flea populations in homes and on
dogs. While the afoxolaner chewable was administered
three times at monthly intervals, fluralaner eliminated fleas
on dogs and in the homes within 12 weeks following a sin-
gle dose. Not only were flea populations controlled by these
formulations, but marked improvement in dermatologic
lesions and pruritus were also observed without the use of
any concurrent medical intervention.
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